http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011153156-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_078cc88f5fa7ef3040e10efdc45d9b57 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 |
| filingDate | 2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf9b6ca1bd6d0eb9fc15d7ea7b4a8554 |
| publicationDate | 2011-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2011153156-A |
| titleOfInvention | Compositions for treating various eye diseases comprising an activator of sirtuin |
| abstract | [PROBLEMS] Glaucoma, high-tension glaucoma, normal-tension glaucoma, angiogenic senile macular degeneration, senile macular lesions, central choroiditis, macular degeneration, senile macular degeneration, macular hole, cataract Senile cataract, fundus hemorrhage, central retinal artery occlusion, fundus arteriosclerosis, photovision, diabetic retinopathy, retina choroidal atrophy, fundus lesion by myopia, retinal and choroidal neovascularization, retinoblastoma, Malignant melanoma or other malignant tumors, cataracts by removal of ovaries, cataracts by TGFβ, macular fibroproliferation (macular macular), central retinal vein (branch) obstruction, retinal tear, retinal detachment, proliferative retinopathy, retina Pigmentary degeneration, keratitis, corneal opacity, corneal bilan, corneal epithelial detachment, corneal ulcer, Morlens corneal ulcer, corneal endothelial cell degeneration or shedding, corneal degeneration, epidemic keratoconjunctivitis, chalazion, iritis, uveitis, Autoimmune disease , Retina choroiditis, iridocyclitis, eye strain, visual field narrowing due to various diseases, optic nerve atrophy, optic neuritis, ischemic optic neuropathy, decreased visual acuity, color vision abnormality, presbyopia, myopia, hyperopia, astigmatism A novel pharmaceutical composition for effectively treating various eye diseases such as the above. A composition for treating ophthalmic diseases comprising a substance that activates sirtuin. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019055925-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2830552-A4 |
| priorityDate | 2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.